title: Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually.
authors: Calvary Mater Newcastle, Newcastle, NSW, Australia. craig.gedye@calvarymater.org.au.
authors: Craig
authors: C
authors: Gedye
authors: Mater Hospital, Sydney, NSW, Australia.
authors: Frances M
authors: FM
authors: Boyle
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D001315:Australia; D017046:Cost Savings; D016527:Drug Costs; D017048:Health Care Costs; D006801:Humans; D007093:Imidazoles / Q000191:economics / Q000627:therapeutic use; D007167:Immunotherapy / Q000191:economics*; D000074324:Ipilimumab; D008545:Melanoma / Q000191:economics* / Q000556:secondary / Q000628:therapy; D010091:Oximes / Q000191:economics / Q000627:therapeutic use; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D016032:Randomized Controlled Trials as Topic
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D007093:Imidazoles; D000074324:Ipilimumab; D010091:Oximes; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib